The link between metabolism and reproduction is gaining attention, especially as questions about GLP-1 therapy and male fertility begin to surface in clinical practice. For years, male fertility evaluations focused mainly on hormones and anatomy. However, what if the root problem starts with metabolic health? Obesity and insulin resistance are …
Read More »GLP-1s and Chronic Pain: Anti-Inflammatory Effect or Weight-Driven Relief?
Patients using GLP-1 receptor agonists are reporting something unexpected: less joint and musculoskeletal pain. As interest grows in how GLP-1 therapies may affect chronic pain, clinicians are asking an important question. Are these improvements simply the result of weight loss, or do GLP-1 medications have direct anti-inflammatory and neuromodulatory effects? …
Read More »Nutrition Equity in Diabetes: Addressing Food Insecurity Without the Paperwork
Diabetes management often begins with nutrition advice. However, what happens when patients cannot afford fresh produce or live miles from a grocery store? For many people living with diabetes, food insecurity is a growing yet underrecognized barrier to glycemic control. While clinicians routinely discuss carbohydrate counting and meal planning, they …
Read More »Bringing CGM Into the Primary Care Visit: Practical Integration for Non-Specialists
Continuous glucose monitoring was once reserved for endocrinology clinics. Today, integrating CGM into primary care is essential as guidelines recommend earlier and broader use in both type 1 and type 2 diabetes. Yet many clinicians still feel unsure about how to interpret reports or fit CGM into a busy visit. …
Read More »CKM in the Wild: Applying the 2026 ADA Cardiometabolic Framework to a Real Panel
What happens when a guideline finally reflects the complex realities of patient care? The ADA’s 2026 CKM standards aim to do just that—merging heart, kidney, and metabolic health into one actionable framework. But translating those recommendations into daily clinical decision-making isn’t always straightforward. This article walks through real-world composite cases …
Read More »GLP‑1s in Menopause: Using Incretins to Protect Cardiometabolic Health in Midlife
Menopause marks a major transition in a woman’s life, defined not only by the end of menstrual cycles but also by profound hormonal and metabolic changes. One often under‑recognized shift is the acceleration of cardiometabolic risk. Women in midlife frequently experience increased central adiposity, changes in glucose regulation, rising blood …
Read More »Inside the ADA 2026 Guidelines: A New Cardiometabolic Roadmap for Diabetes Care
The updated ADA 2026 standards represent a major shift in how clinicians approach diabetes management. Rather than focusing solely on lowering A1C, these new recommendations promote a broader, holistic strategy that integrates cardiovascular, kidney, and metabolic (CKM) risk management into everyday care. This article breaks down the key updates and …
Read More »Mental Health and Diabetes: When to Refer and How to Collaborate
Living with diabetes can take a serious toll on a person’s mental well-being. Depression, anxiety, and other psychiatric conditions often go hand-in-hand with chronic illnesses, and diabetes is no exception. Yet, despite the deep connection between mental health and diabetes, care for these conditions remains siloed. This article gives clinicians …
Read More »Prescribing Exercise in Type 2 Diabetes: What the Evidence Says About Type, Dose, and Impact
Exercise is a cornerstone of type 2 diabetes care, yet clinicians often struggle with translating broad guidelines into practical, individualized “exercise prescriptions.” The focus keyword in this article, exercise prescription for type 2 diabetes, reflects a high‑intent search term that clinicians, diabetes educators, and patients frequently use when seeking actionable …
Read More »Beyond GLP‑1s: Are We Overlooking the Role of SGLT2 Inhibitors and Metformin?
Clinicians and care teams are increasingly focused on GLP‑1 receptor agonists, but SGLT2 inhibitors and metformin in diabetes management remain foundational in achieving comprehensive, evidence‑based outcomes. While GLP‑1 therapies generate headlines for weight loss and glucose control, 2025 guidelines still strongly emphasize the cardioprotective and renoprotective benefits of SGLT2 inhibitors …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.